公开(公告)号：US20060104899A1

公开(公告)日：2006-05-18

申请号：US11216033

申请日：2005-09-01

Applicant: Hans Hansen ,  Gary Griffiths ,  Shui-on Leung ,  William McBride ,  Zhengxing Qu

Inventor： Hans Hansen ,  Gary Griffiths ,  Shui-on Leung ,  William McBride ,  Zhengxing Qu

IPC: A61K51/00 ,  A61K39/395 ,  A61K49/16

CPC classification number: C07K16/468 ,  A61K47/6863 ,  A61K47/6899 ,  A61K51/1048 ,  A61K51/1063 ,  A61K2039/505 ,  B82Y5/00 ,  C07K16/18 ,  C07K16/30 ,  C07K16/3007 ,  C07K16/3046 ,  C07K16/44 ,  C07K2317/12 ,  C07K2317/13 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/55 ,  C07K2317/622 ,  C07K2319/00

Abstract: The present invention relates to a bi-specific antibody or antibody fragment having at least one arm that is reactive against a targeted tissue and at least one other arm that is reactive against a linker moiety. The linker moiety encompasses a hapten to which antibodies have been prepared. The antigenic linker is conjugated to one or more therapeutic or diagnostic agents or enzymes. The invention provides constructs and methods for producing the bispecific antibodies or antibody fragments, as well as methods for using them.

公开(公告)号：US20050100543A1

公开(公告)日：2005-05-12

申请号：US10882151

申请日：2004-07-01

Applicant: Hans Hansen ,  William McBride ,  Zhengxing Qu

Inventor： Hans Hansen ,  William McBride ,  Zhengxing Qu

IPC: A61K20060101 ,  A61K39/395 ,  A61K47/48 ,  A61K51/08 ,  A61K51/10 ,  C07K16/28 ,  C07K16/30 ,  C07K16/44 ,  C12N9/00

CPC classification number: C07K16/2887 ,  A61K47/6897 ,  A61K51/1027 ,  A61K51/1048 ,  A61K51/109 ,  A61K2039/505 ,  B82Y5/00 ,  C07K16/3007 ,  C07K2317/31 ,  C07K2317/622 ,  C07K2319/00 ,  C07K2319/01

Abstract: Provided herein are targetable constructs that are multivalent carriers of bi-specific antibodies, i.e., each molecule of a targetable construct can serve as a carrier of two or more bi-specific antibodies. Also provided are targetable complexes formed by the association of a targetable construct with two or more bi-specific antibodies. The targetable constructs and targetable complexes of the invention are incorporated into biosensors, kits and pharmaceutical compositions, and are used in a variety of therapeutic and other methods.

Abstract translation: 本文提供作为双特异性抗体的多价载体的可靶向构建体，即可靶向构建体的每个分子可以用作两种或更多种双特异性抗体的载体。 还提供了通过可靶向构建体与两种或更多种双特异性抗体缔合形成的可靶向复合物。 将本发明的可靶向构建体和可靶向复合物掺入生物传感器，试剂盒和药物组合物中，并且以多种治疗和其它方法使用。

公开(公告)号：US20060034759A1

公开(公告)日：2006-02-16

申请号：US11198846

申请日：2005-08-08

Applicant: David Goldenberg ,  Hans Hansen ,  Shui-on Leung ,  William McBride ,  Zhengxing Qu

Inventor： David Goldenberg ,  Hans Hansen ,  Shui-on Leung ,  William McBride ,  Zhengxing Qu

IPC: A61K51/00 ,  C07K7/06 ,  C07K16/46

CPC classification number: A61K51/1048 ,  A61K47/665 ,  A61K47/6879 ,  A61K51/1063 ,  A61K2039/505 ,  B82Y5/00 ,  C07K5/0215 ,  C07K5/1016 ,  C07K5/1019 ,  C07K7/06 ,  C07K16/18 ,  C07K16/3007 ,  C07K16/3046 ,  C07K16/44 ,  C07K16/468 ,  C07K2317/12 ,  C07K2317/13 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/55 ,  C07K2317/622 ,  C07K2317/64 ,  C07K2319/00

Abstract: The present invention relates to a bi-specific antibody or antibody fragment having at least one arm that specifically binds a targeted tissue and at least one other arm that specifically binds a targetable construct. The targetable construct comprises a carrier portion which comprises or bears at least one epitope recognizable by at least one arm of said bi-specific antibody or antibody fragment. The targetable construct further comprises one or more therapeutic or diagnostic agents or enzymes. The invention provides constructs and methods for producing the bi-specific antibodies or antibody fragments, as well as methods for using them.

公开(公告)号：US07435803B2

公开(公告)日：2008-10-14

申请号：US11534103

申请日：2006-09-21

Applicant: Hans Hansen ,  Zhengxing Qu ,  David M. Goldenberg

Inventor： Hans Hansen ,  Zhengxing Qu ,  David M. Goldenberg

IPC: C07K16/00 ,  C12P21/08 ,  A61K39/395 ,  G01N33/574 ,  C12P21/04 ,  C07H21/04

CPC classification number: C07K16/2803 ,  A61K2039/505 ,  A61K2039/507 ,  C07K16/2887 ,  C07K2317/24 ,  C07K2317/56

Abstract: The present invention provides humanized, chimeric and human anti-CD20 antibodies and CD 20 antibody fusion proteins that bind to a human B cell marker, referred to as CD20, which is useful for the treatment and diagnosis of B-cell disorders, such as B-cell malignancies and autoimmune diseases, and methods of treatment and diagnosis.

Abstract translation: 本发明提供结合人B细胞标记（称为CD20）的人源化，嵌合和人抗CD20抗体和CD20抗体融合蛋白，其可用于治疗和诊断B细胞疾病，例如B 细胞恶性肿瘤和自身免疫性疾病，以及治疗和诊断的方法。

公开(公告)号：US20070212350A1

公开(公告)日：2007-09-13

申请号：US11745896

申请日：2007-05-08

Applicant: Serengulam Govindan ,  Zhengxing Qu ,  Hans Hansen ,  David Goldenberg

Inventor： Serengulam Govindan ,  Zhengxing Qu ,  Hans Hansen ,  David Goldenberg

IPC: A61K39/44 ,  A61K39/395 ,  C07K16/30 ,  C12P21/08

CPC classification number: A61K45/06 ,  A61K39/39558 ,  A61K51/1045 ,  A61K51/1051 ,  A61K2039/505 ,  C07K16/30 ,  C07K16/3015 ,  C07K2317/21 ,  C07K2317/24

Abstract: This invention relates to monovalent and multivalent, monospecific binding proteins and to multivalent, multispecific binding proteins. One embodiment of these binding proteins has one or more binding sites where each binding site binds with a target antigen or an epitope on a target antigen. Another embodiment of these binding proteins has two or more binding sites where each binding site has affinity towards different epitopes on a target antigen or has affinity towards either a target antigen or a hapten. The present invention further relates to recombinant vectors useful for the expression of these functional binding proteins in a host. More specifically, the present invention relates to the tumor-associated antigen binding protein designated RS7, and other EGP-1 binding-proteins. The invention further relates to humanized, human and chimeric RS7 antigen binding proteins, and the use of such binding proteins in diagnosis and therapy.

Abstract translation: 本发明涉及单价和多价单特异性结合蛋白和多价多特异性结合蛋白。 这些结合蛋白的一个实施方案具有一个或多个结合位点，其中每个结合位点与靶抗原或靶抗原上的表位结合。 这些结合蛋白的另一个实施方案具有两个或更多个结合位点，其中每个结合位点对靶抗原上的不同表位具有亲和力，或对靶抗原或半抗原具有亲和力。 本发明还涉及可用于在宿主中表达这些功能性结合蛋白的重组载体。 更具体地，本发明涉及称为RS7的肿瘤相关抗原结合蛋白和其它EGP-1结合蛋白。 本发明还涉及人源化，人和嵌合RS7抗原结合蛋白，以及这种结合蛋白在诊断和治疗中的用途。

公开(公告)号：US06254868B1

公开(公告)日：2001-07-03

申请号：US09155107

申请日：1998-11-17

Applicant: Shui-on Leung ,  Hans Hansen ,  Zhengxing Qu

Inventor： Shui-on Leung ,  Hans Hansen ,  Zhengxing Qu

IPC: A61K39395

CPC classification number: C07K16/2803 ,  A61K38/00 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/41 ,  C07K2317/54 ,  C07K2317/77 ,  C07K2319/00

Abstract: A humanized specific monoclonal antibody or antibody fragment, especially a B-cell specific antibody or antibody fragment, is engineered to contain a glyxosylation site in the non-Fc constant region. The glycosylated antibody is useful for diagnosis and/or therapy whenever a targeting antibody or fragment is used, especially for B-cell malignancies. The carbohydrate moiety allows conjugation of labeling or therapeutic agents of increased size, without affecting the binding affinity or specificity of the antibody.

Abstract translation: 将人源化特异性单克隆抗体或抗体片段，特别是B细胞特异性抗体或抗体片段设计成含有非Fc恒定区中的糖基化位点。 只要使用靶向抗体或片段，特别是B细胞恶性肿瘤，糖基化抗体可用于诊断和/或治疗。 碳水化合物部分允许增加大小的标记或治疗剂的缀合，而不影响抗体的结合亲和力或特异性。

公开(公告)号：US08057793B2

公开(公告)日：2011-11-15

申请号：US12212359

申请日：2008-09-17

Applicant: Hans Hansen ,  Zhengxing Qu ,  David M. Goldenberg

Inventor： Hans Hansen ,  Zhengxing Qu ,  David M. Goldenberg

IPC: A61K39/00 ,  A61K39/395

CPC classification number: C07K16/2803 ,  A61K2039/505 ,  A61K2039/507 ,  C07K16/2887 ,  C07K2317/24 ,  C07K2317/56

Abstract: The present invention provides humanized, chimeric and human anti-CD20 antibodies and CD20 antibody fusion proteins that bind to a human B cell marker, referred to as CD20, which is useful for the treatment and diagnosis of B-cell disorders, such as B-cell malignancies and autoimmune diseases, and methods of treatment and diagnosis.

Abstract translation: 本发明提供结合人B细胞标记（称为CD20）的人源化，嵌合和人抗CD20抗体和CD20抗体融合蛋白，其可用于治疗和诊断B细胞病症，例如B- 细胞恶性肿瘤和自身免疫疾病，以及治疗和诊断的方法。

公开(公告)号：US20080131363A1

公开(公告)日：2008-06-05

申请号：US11868290

申请日：2007-10-05

Applicant: Serengulam Govindan ,  Zhengxing Qu ,  Hans Hansen ,  David Goldenberg

Inventor： Serengulam Govindan ,  Zhengxing Qu ,  Hans Hansen ,  David Goldenberg

IPC: A61K39/395 ,  A61K38/20 ,  A61K51/10 ,  A61P35/04

CPC classification number: C07K16/30 ,  A61K38/164 ,  A61K38/168 ,  A61K38/1816 ,  A61K38/19 ,  A61K38/21 ,  A61K45/06 ,  A61K47/6805 ,  A61K47/6857 ,  A61K51/1054 ,  A61K2039/505 ,  C07K16/28 ,  C07K2317/24 ,  C07K2317/56 ,  C07K2317/94 ,  A61K2300/00

Abstract: This invention relates to monovalent and multivalent, monospecific binding proteins and to multivalent, multispecific binding proteins. One embodiment of these binding proteins has one or more binding sites where each binding site binds with a target antigen or an epitope on a target antigen. Another embodiment of these binding proteins has two or more binding sites where each binding site has affinity towards different epitopes on a target antigen or has affinity towards either a target antigen or a hapten. The present invention further relates to recombinant vectors useful for the expression of these functional binding proteins in a host. More specifically, the present invention relates to the tumor-associated antigen binding protein designated RS7, and other EGP-1 binding-proteins. The invention further relates to humanized, human and chimeric RS7 antigen binding proteins, and the use of such binding proteins in diagnosis and therapy.

Abstract translation: 本发明涉及单价和多价单特异性结合蛋白和多价多特异性结合蛋白。 这些结合蛋白的一个实施方案具有一个或多个结合位点，其中每个结合位点与靶抗原或靶抗原上的表位结合。 这些结合蛋白的另一个实施方案具有两个或更多个结合位点，其中每个结合位点对靶抗原上的不同表位具有亲和力，或对靶抗原或半抗原具有亲和力。 本发明还涉及可用于在宿主中表达这些功能性结合蛋白的重组载体。 更具体地，本发明涉及称为RS7的肿瘤相关抗原结合蛋白和其它EGP-1结合蛋白。 本发明还涉及人源化，人和嵌合RS7抗原结合蛋白，以及这种结合蛋白在诊断和治疗中的用途。

公开(公告)号：US20070020259A1

公开(公告)日：2007-01-25

申请号：US11534103

申请日：2006-09-21

Applicant: Hans Hansen ,  Zhengxing Qu ,  David Goldenberg

Inventor： Hans Hansen ,  Zhengxing Qu ,  David Goldenberg

IPC: A61K39/395 ,  C07H21/04 ,  C12P21/06 ,  C07K16/44 ,  C12N5/06

CPC classification number: C07K16/2803 ,  A61K2039/505 ,  A61K2039/507 ,  C07K16/2887 ,  C07K2317/24 ,  C07K2317/56

Abstract: The present invention provides humanized, chimeric and human anti-CD20 antibodies and CD 20 antibody fusion proteins that bind to a human B cell marker, referred to as CD20, which is useful for the treatment and diagnosis of B-cell disorders, such as B-cell malignancies and autoimmune diseases, and methods of treatment and diagnosis.

Abstract translation: 本发明提供结合人B细胞标记（称为CD20）的人源化，嵌合和人抗CD20抗体和CD20抗体融合蛋白，其可用于治疗和诊断B细胞疾病，例如B 细胞恶性肿瘤和自身免疫性疾病，以及治疗和诊断的方法。

公开(公告)号：US20060257398A1

公开(公告)日：2006-11-16

申请号：US11445410

申请日：2006-06-01

Applicant: Hans Hansen ,  Zhengxing Qu ,  David Goldenberg

Inventor： Hans Hansen ,  Zhengxing Qu ,  David Goldenberg

IPC: A61K39/395 ,  C07K16/44 ,  C07K16/28

CPC classification number: C07K16/2803 ,  A61K2039/507 ,  C07K16/2887 ,  C07K2317/565

Abstract: The present invention provides humanized, chimeric and human anti-CD19 antibodies, anti-CD19 antibody fusion proteins, and fragments thereof that bind to a human B cell marker. Such antibodies, fusion proteins and fragments thereof are useful for the treatment and diagnosis of various B-cell disorders, including B-cell malignancies and autoimmune diseases.

Abstract translation: 本发明提供了结合人B细胞标记的人源化，嵌合和人抗CD19抗体，抗-CD19抗体融合蛋白及其片段。 此类抗体，融合蛋白及其片段可用于治疗和诊断各种B细胞病症，包括B细胞恶性肿瘤和自身免疫性疾病。